X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4385) 4385
Publication (462) 462
Book Review (72) 72
Magazine Article (10) 10
Book Chapter (9) 9
Book / eBook (3) 3
Newspaper Article (3) 3
Reference (3) 3
Dissertation (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3754) 3754
imatinib mesylate (3058) 3058
index medicus (2377) 2377
male (1878) 1878
female (1873) 1873
benzamides (1815) 1815
oncology (1711) 1711
middle aged (1593) 1593
pyrimidines - therapeutic use (1408) 1408
adult (1374) 1374
antineoplastic agents - therapeutic use (1323) 1323
piperazines - therapeutic use (1303) 1303
pyrimidines - adverse effects (1246) 1246
aged (1204) 1204
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1196) 1196
piperazines - adverse effects (1140) 1140
antineoplastic agents - adverse effects (1088) 1088
imatinib (1007) 1007
hematology (993) 993
treatment outcome (965) 965
chronic myelogenous leukemia (808) 808
chronic myeloid-leukemia (745) 745
cancer (707) 707
protein kinase inhibitors - therapeutic use (684) 684
chronic myeloid leukemia (643) 643
pyrimidines - administration & dosage (635) 635
pharmacology & pharmacy (589) 589
piperazines - administration & dosage (580) 580
mesylate (573) 573
care and treatment (566) 566
animals (545) 545
therapy (522) 522
antineoplastic agents - administration & dosage (482) 482
protein-tyrosine kinases - antagonists & inhibitors (472) 472
protein kinase inhibitors - adverse effects (470) 470
medicine & public health (454) 454
aged, 80 and over (435) 435
adolescent (434) 434
leukemia (433) 433
drug therapy (431) 431
chemotherapy (429) 429
antineoplastic agents (426) 426
research (425) 425
tyrosine kinase inhibitor (423) 423
dasatinib (401) 401
gastrointestinal stromal tumors - drug therapy (398) 398
antimitotic agents (389) 389
young adult (360) 360
prognosis (328) 328
analysis (317) 317
drug resistance, neoplasm (314) 314
hematology, oncology and palliative medicine (311) 311
bcr-abl (309) 309
pyrimidines - pharmacology (306) 306
tumors (306) 306
tyrosine (300) 300
disease-free survival (292) 292
tyrosine kinase inhibitors (286) 286
follow-up studies (284) 284
tyrosine kinase (284) 284
piperazines - pharmacology (281) 281
antineoplastic agents - pharmacology (278) 278
gastrointestinal stromal tumors (275) 275
mutation (274) 274
leukemia, myelogenous, chronic, bcr-abl positive - genetics (271) 271
efficacy (265) 265
dose-response relationship, drug (263) 263
retrospective studies (262) 262
antineoplastic combined chemotherapy protocols - therapeutic use (261) 261
health aspects (258) 258
c-kit (255) 255
time factors (254) 254
leukemia, myelogenous, chronic, bcr-abl positive - pathology (251) 251
nilotinib (250) 250
hemic and lymphatic diseases (249) 249
cml (245) 245
risk factors (241) 241
clinical trials (239) 239
benzamides - therapeutic use (234) 234
protein kinase inhibitors - administration & dosage (232) 232
surgery (226) 226
clinical trials as topic (224) 224
follow-up (219) 219
imatinib mesylate - therapeutic use (218) 218
metastasis (217) 217
fusion proteins, bcr-abl - genetics (213) 213
interferon-alpha (211) 211
survival (210) 210
diagnosis (208) 208
gastrointestinal stromal tumors - pathology (208) 208
gist (208) 208
resistance (206) 206
safety (205) 205
cytogenetic responses (199) 199
benzamides - adverse effects (194) 194
abridged index medicus (192) 192
chronic-phase (191) 191
protein kinase inhibitors - pharmacology (191) 191
inhibitor (190) 190
article (189) 189
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4151) 4151
Japanese (74) 74
French (49) 49
German (47) 47
Chinese (36) 36
Spanish (18) 18
Russian (7) 7
Hungarian (4) 4
Polish (4) 4
Czech (3) 3
Danish (3) 3
Dutch (3) 3
Italian (3) 3
Norwegian (2) 2
Croatian (1) 1
Hebrew (1) 1
Portuguese (1) 1
Serbian (1) 1
Slovenian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 596 - 603
Historically, body tissues with a high rate of cell turnover, such as the bone marrow, have been most susceptible to chemotherapy-induced damage. The... 
PHASE-II TRIAL | ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | ALBUMIN-BOUND PACLITAXEL | BRAIN-TUMOR CONSORTIUM | ACUTE TRANSIENT ENCEPHALOPATHY | CEREBROSPINAL-FLUID PHARMACOKINETICS | OXALIPLATIN-RELATED NEUROTOXICITY | RECURRENT MALIGNANT GLIOMAS | ANALOG IXABEPILONE BMS-247550 | ADVANCED COLORECTAL-CANCER | Dacarbazine - adverse effects | United States | Humans | Antibodies, Monoclonal - adverse effects | Boronic Acids - adverse effects | Drug Approval | Epothilones - adverse effects | Bevacizumab | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | United States Food and Drug Administration | Tubulin Modulators - adverse effects | Bortezomib | Clinical Trials as Topic | Imatinib Mesylate | Piperazines - adverse effects | Neoplasms - drug therapy | Neurotoxicity Syndromes - etiology | Indoles - adverse effects | Pyrazines - adverse effects | Pyrimidines - adverse effects | Benzamides | Antineoplastic Agents, Alkylating - adverse effects | Organoplatinum Compounds - adverse effects | Antimitotic agents | Complications and side effects | Nervous system diseases | Patient outcomes | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Drug therapy | Risk factors | Cancer | Index Medicus
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2013, Volume 98, Issue 4, pp. 1333 - 1342
Context: The use of kinase inhibitors (KIs) in the treatment of cancer has become increasingly common, and practitioners must be familiar with... 
PHASE-II TRIAL | SUNITINIB INDUCES HYPOTHYROIDISM | THYROID-DYSFUNCTION | METASTATIC BREAST-CANCER | ENDOCRINOLOGY & METABOLISM | SECONDARY HYPERPARATHYROIDISM | ALTERED BONE | MONOCLONAL-ANTIBODIES | RENAL-CELL CARCINOMA | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA
Journal Article
Journal Article
Pediatrics International, ISSN 1328-8067, 03/2017, Volume 59, Issue 3, pp. 286 - 292
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 03/2018, Volume 57, Issue 3, pp. 332 - 338
Background Short‐term mucocutaneous adverse effects are well documented with imatinib. However, studies on long‐term adverse effects and in the ethnic... 
TYROSINE KINASE INHIBITORS | MESYLATE | PORPHYRIA-CUTANEA-TARDA | THERAPY | SECONDARY | DASATINIB | SKIN | NILOTINIB | DERMATOLOGY | Antimitotic agents | Complications and side effects | Chronic myeloid leukemia | Antineoplastic agents | Analysis | Edema | Imatinib | Hematology | Myeloid leukemia | Leukemia | Multivariate analysis | Patients | Pigmentation | Risk factors | Side effects | Eruptions | Hyperpigmentation | Females
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 11, pp. 2449 - 2457
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Journal Article